Document is current
Any future updates will be listed below
-
Authors
,
Rozenblatt-Rosen, Orit
Shin, Jay W. https://orcid.org/0000-0003-4037-3533
Rood, Jennifer E.
Hupalowska, Anna
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Heyn, Holger https://orcid.org/0000-0002-3276-1889
-
Funding
Funding for this research was provided by:
MEXT | JST | Accelerated Innovation Research Initiative Turning Top Science and Ideas into High-Impact Values
Howard Hughes Medical Institute
BCH | Manton Center for Orphan Disease Research, Boston Children’s Hospital
Klarman Cell Observatory Manton Foundation
EC | Horizon 2020 Framework Programme (810287, 874710)
Silicon Valley Community Foundation (2018-182827, HCA-A-1704-01742)
Ministerio de Ciencia, Innovación y Universidades
- License Information
-
More Information
Article History
First Online: 26 January 2021
Competing interests
: A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and an SAB member of ThermoFisher Scientific, Syros Pharmaceuticals, Asimov and Neogene Therapeutics. A.R. is a co-inventor on patent applications to advances in single-cell genomics, including droplet-based sequencing technologies, as in PCT/US2015/0949178, and methods for expression and analysis, as in PCT/US2016/059233 and PCT/US2016/059239. O.R.R. is a co-inventor on patent applications filed by the Broad Institute for inventions relating to single-cell genomics, such as in PCT/US2018/060860 and US Provisional Application No. 62/745259.
